Loading...
XSTO
TOL
Market cap13mUSD
May 26, Last price  
0.47SEK
1D
2.38%
1Q
11.29%
Jan 2017
-91.02%
IPO
-93.72%
Name

Toleranzia AB

Chart & Performance

D1W1MN
P/E
—
P/S
4.27
EPS
—
Div Yield, %
—
Shrs. gr., 5y
61.21%
Rev. gr., 5y
34.00%
Revenues
30m
-41.03%
6,227,6583,164,972309,00466,0103,631,0262,532,3304,277,8836,949,43712,881,50027,589,00035,367,00050,920,00030,026,000
Net income
-9m
L+26.50%
40,19638,959-737,223-4,109,695-5,055,571-5,391,991-5,657,963-9,929,020-4,894,585-6,283,865-8,456,000-7,459,000-9,436,000
CFO
-10m
L+62.58%
00-935,224-3,361,268-5,251,146-5,605,743-4,822,947-4,432,966-3,991,297-6,849,365-7,200,000-6,323,000-10,280,000

Profile

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was founded in 2011 and is headquartered in Gothenburg, Sweden.
URL
https://www.toleranzia.com/
IPO date
Dec 16, 2015
Employees
14
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
30,026
-41.03%
50,920
43.98%
35,367
28.19%
Cost of revenue
34,170
51,839
(35,257)
Unusual Expense (Income)
NOPBT
(4,144)
(919)
70,624
NOPBT Margin
199.69%
Operating Taxes
(17,076)
Tax Rate
NOPAT
(4,144)
(919)
87,700
Net income
(9,436)
26.50%
(7,459)
-11.79%
(8,456)
34.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
36,946
43,378
BB yield
-29.42%
-76.13%
Debt
Debt current
Long-term debt
850
850
Deferred revenue
Other long-term liabilities
(850)
Net debt
(13,777)
(17,454)
(33,087)
Cash flow
Cash from operating activities
(10,280)
(6,323)
(7,200)
CAPEX
(211)
(35,141)
Cash from investing activities
(30,237)
(50,778)
(35,141)
Cash from financing activities
35,992
41,468
FCF
(4,294)
(894)
87,670
Balance
Cash
13,777
18,304
33,937
Long term investments
Excess cash
12,276
15,758
32,169
Stockholders' equity
(199,833)
(30,876)
(34,261)
Invested Capital
379,906
185,244
154,620
ROIC
56.72%
ROCE
58.68%
EV
Common stock shares outstanding
211,405
133,133
110,315
Price
0.59
38.79%
0.43
-61.79%
1.12
-5.08%
Market cap
125,575
120.38%
56,981
-53.88%
123,553
48.83%
EV
111,798
39,527
90,466
EBITDA
(4,934)
(894)
70,641
EV/EBITDA
1.28
Interest
95
19
Interest/NOPBT
0.03%